2014 10 21 Bo Poliwogg Poster

JLABS | Meet with... Poliwogg

October 21, 2014

Share :

Time: 10:30AM - 12:30PM
Location: Lobby

RSVP after requesting the LabCentral code for free entry from Clancy

The rise of alternative funding has forever changed the way money is raised, and Poliwogg is capitalizing on that shift to help life science startups and transform healthcare investing. Poliwogg is interested in innovative early stage companies across all areas of healthcare and life sciences, including biopharmaceuticals, diagnostics, devices, health IT, and big data.

Samuel Wertheimer, Poliwogg Chief Investment Officer and Brock Reeve, Poliwogg Portfolio Manager, will be in attendance on Tuesday, October 21st to give an overview presentation on the organization's key areas of interest and best practices when seeking funding. Attendees will also get the latest scoop on Poliwogg's "Innovation Funds,", a new series of publicly registered venture funds with investments ranging from $500k to $5m. Following the presentation, don't miss this opportunity to introduce yourself to Poliwogg representatives during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with representatives from Poliwogg will provide a forum to discuss your company. For more details please see the agenda on the RSVP page.

Don't miss the opportunity to meet one-on-one with Poliwogg: apply today!

About the "Meet with..." series:
The purpose of the "Meet with..." series events sponsored by Janssen Labs is to help start-up entrepreneurs as well as the academic community connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include: Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, Correlation Ventures, Breakout Labs, and Thomas McNerney & Partners.